Recent IFRX News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/08/2024 12:43:48 PM
- InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/08/2024 11:30:00 AM
- InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024 • GlobeNewswire Inc. • 04/30/2024 11:30:00 AM
- InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event • GlobeNewswire Inc. • 04/24/2024 11:30:00 AM
- InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans • GlobeNewswire Inc. • 03/21/2024 11:00:00 AM
- InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024 • GlobeNewswire Inc. • 03/19/2024 11:30:00 AM
- InflaRx Appoints Jan Medina as Head of Investor Relations • GlobeNewswire Inc. • 02/22/2024 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/25/2024 01:00:15 PM
- InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients • GlobeNewswire Inc. • 01/25/2024 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/04/2024 09:16:17 PM
- InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904 • GlobeNewswire Inc. • 01/04/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/06/2023 01:00:09 PM
- InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum • GlobeNewswire Inc. • 11/06/2023 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/01/2023 12:04:10 PM
- InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 11/01/2023 11:30:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/11/2023 12:45:50 PM
- InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904 • GlobeNewswire Inc. • 09/11/2023 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/30/2023 12:00:10 PM
- InflaRx’s Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA) • GlobeNewswire Inc. • 08/30/2023 11:30:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/10/2023 12:00:40 PM
- InflaRx Reports Second Quarter 2023 Financial Results & Operating Update • GlobeNewswire Inc. • 08/10/2023 11:30:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/12/2023 08:01:45 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 07/12/2023 04:15:08 AM
- Form F-3 - Registration statement by foreign private issuers • Edgar (US Regulatory) • 06/30/2023 08:06:11 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/28/2023 12:30:36 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM